Clinical trials: Hodgkin Lymphoma
B-cell Lymphoma
Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma
Phase II, multi-centric, open-label, study. Disseminated diffuse large B-cell lymphoma in patients older than 60: evaluation of fractionated radio-immunotherapy with 90Y-DOTA-hLL2 as a consolidation therapy after first line of…
- Trial name
- NCT00906841
- Testing
- 90Y-DOTA-hLL2
- Where
- France
- Volunteers
- 75 people
- Sponsor
- French Innovative Leukemia Organisation
Lymphoma
Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00003541
- Testing
- filgrastim, CHOP regimen, carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Hodgkin T-cell Lymphoma
Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study
The better understanding of non-Hodgkin T-cell lymphoma is essential for establishing effective treatment strategy for non-Hodgkin T-cell lymphoma.
- Trial name
- NCT02691351
- Testing
- Prospective Registry
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Samsung Medical Center
Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma
The purpose of this research study is to determine the highest and safest dose of the experimental drug veliparib when combined with nivolumab.
- Conditions
- Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm, Refractory Mantle Cell Lymphoma
- Trial name
- NCT03061188
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Lymphoma
New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma
The purpose of this study is to evaluate the efficacy and tolerability of the combination chemotherapy of L-asparaginase plus DICE regimen in the patients with early stage NK/T-cell lymphoma.
- Trial name
- NCT00933673
- Testing
- L-asp, DXM, IFO, VP-16, DDP
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fudan University
Diffuse Large B-cell Lymphoma
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00474188
- Testing
- CC-5013 (lenalidomide), dexamethasone
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Celgene Corporation
Diffuse Large B-Cell Lymphoma
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Primary Objective: Participants Achieving an Objective Response Rate (Cheson 2007) Secondary Objectives: Progression Free Survival Overall Survival Response Duration
- Trial name
- NCT01470456
- Testing
- SAR3419, rituximab
- Where
- 13 sites in Austria, France and 1 more
- Volunteers
- 50 people
- Sponsor
- Sanofi
Relapsed NLPHL
Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).
- Trial name
- NCT01187303
- Testing
- Ofatumumab
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- University of Cologne
Lymphoma
Dose-Dense Therapy in Aggressive Lymphoma
To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.
- Trial name
- NCT00517894
- Testing
- CEOP/IMVP-Dexa chemotherapy
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Hodgkin´s Lymphoma
HD12 for Advanced Stages
This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.
- Trial name
- NCT00265031
- Testing
- Cyclophosphamide, Adriamycin, Etoposide
- Sponsor
- University of Cologne
Hematologic Malignancies
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.
- Trial name
- NCT00881946
- Testing
- GSK21110183
- Where
- 4 sites in Australia, Canada and 1 more
- Volunteers
- 73 people
- Sponsor
- Accenture
Peripheral T-Cell Lymphoma
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
This study will determine the maximum dose of KW-0761 administered intravenously that can be given safely in subjects with previously treated peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma(CTCL)and will see if it…
- Trial name
- NCT00888927
- Testing
- KW-0761
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Relapsed Peripheral T-Cell Lymphomas, Refractory Peripheral T-Cell Lymphomas
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with CAOLD Regimen in the treatment of relapsed/refractory peripheral t-cell…
- Trial name
- NCT06176027
- Testing
- Azacytidine plus CAOLD regimen
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Navy General Hospital, Beijing
Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission
Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma
This is a single-arm open-label phase I/II study to determine the relative superiority of αCD19-TCRζ-CD28 and αCD19-TCRζ-CD137 CAR-T Cells in safety, efficacy and engraftment potential in patients with CD19+ B-lineage leukemia…
- Conditions
- Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia
- Trial name
- MatchCART (NCT02685670)
- Testing
- anti-CD19 CAR-T, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Hodgkin Lymphoma, Lymphoma, Large B-Cell, Diffuse
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas
To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), Hodgkin Lymphoma (HL) and Post-transplant Lymphoproliferative Disease…
- Conditions
- Hodgkin Lymphoma, Lymphoma, Large B-Cell, Diffuse, Post-transplant Lymphoproliferative Disorder
- Trial name
- CIVIC (NCT02763254)
- Testing
- baltaleucel-T
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Cell Medica Ltd
Hodgkin Disease
Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma
The aim of this study is to analyze the efficacy of O-ESHAP treatment for Hodgkin's lymphome patients that have a first line chemotherapy treatment failure due to refractoriness, partial response or relapsed.
- Trial name
- NCT01195766
- Testing
- Ofatumumab
- Where
- 14 sites in Spain
- Volunteers
- 64 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Leukemia, Lymphoma
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Aldesleukin may stimulate natural killer cells to kill cancer cells. Treating natural killer cells with aldesleukin in the laboratory may help the natural killer cells kill more cancer cells when they are put back in…
- Trial name
- NCT00625729
- Testing
- aldesleukin, allogeneic natural killer cells, rituximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma, Low-Grade
Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL
The purpose of this study is to assess the antitumor effect and safety of fludarabine phosphate tablet in combination with rituximab in patient with indolent lymphoma.
- Trial name
- NCT00311129
- Testing
- Fludarabine Phosphate (Fludara), Rituximab
- Where
- 8 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma, Follicular
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to evaluate the efficacy (effectiveness) and tolerability (how well a participant can stand a particular medicine or treatment; ability to be used) of bortezomib in combination with rituximab standard…
- Trial name
- NCT01902862
- Testing
- Bortezomib, Rituximab
- Where
- 3 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Janssen-Cilag G.m.b.H
Non Hodgkin Lymphoma
RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy
This study is an open-label Phase II trial of non-Hodgkin lymphoma patients receiving initial treatment with the immunomodulatory agent, pembrolizumab, plus low-dose (4 Gy x 5) involved-site radiotherapy.
- Trial name
- NCT04827862
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.